Diverse perspectives on science and medicine
A few days ago, in a courtroom in India, a landmark ruling was made that could impact future legal battles over the sale of generic versions of expensive medications in India. When the Delhi High
Yesterday, the Oncologic Drugs Advisory Committee issued its recommendation to the FDA on the use of Avastin for the treatment of breast cancer: no. Based on clinical trial results, ODAC members voted unanimously that the
Here is a current story that illustrates some of the major conundrums of modern drug development and health care. For those who are familiar with this little tale-in-progress, my guess is that you are, like
Despite all the hullabaloo over the healthcare reform bill, there are still some aspects that have not entered public discussion. Or, at least one aspect: data exclusivity for biologics. It’s a lot more interesting than
What a thrill to be launching this new contribution to the PLoS Blog Network. Thank you for visiting this page. It’s an honor to be here, and I hope to serve you well with thought-provoking